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A 26-year-old  overweight  female  patient  presented  to  the
mergency  department  with  severe  odynophagia  for  six  days
nd  retrosternal  pain  in  the  past  two  weeks.  She  had  a  his-
ory  of  appendectomy  and  a  recent  diagnosis  of  irritable∗ Corresponding author.
E-mail address: lidia.roque.ramos@gmail.com
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ation  or  recent  use  of  any  drugs,  namely  antibiotics  or
on-steroidal  anti-inﬂammatory  drugs.  Laboratory  studies
howed  an  increased  C-reactive  protein  and  a negative  HIV
erology.  An  esophagogastroduodenoscopy  (EGD)  revealed
everal  ulcers  in  the  lower  third  of  the  esophagus,  the  largest
ith  15  mm  and  raised  borders  (Fig.  1).  Biopsies  were  taken
rom  the  edges  and  bottom  of  the  ulcer.  The  patient  was
dmitted  and  empirically  started  on  proton  pump  inhibitor
PPI)  and  acyclovir.  Serologies  ruled  out  HSV  1  and  2,  CMV,
BV  and  VZV  recent  infections  and  syphilis.  Histological
xamination  showed  an  intense  chronic  inﬂammatory  inﬁl-
rate  involving  the  mucosal,  submucosal  and  muscular  layers
Fig.  2a)  and  an  epithelioid  granuloma  with  a  giant  cell
Fig.  2b).  There  were  no  viral  cytopathic  effects  or  acid-fast
acilli.  Hence,  our  patient  had  a  non-caseous  esophageal
ranulatomatosis.  We  excluded  tuberculosis,  sarcoidosis  and
ranulomatosis  with  polyangiits  (Wegener’s  granulomatosis)
ased  on  a  negative  Mantoux  and  IGRA  tests  and  normal
hest  X-ray,  angiotensin  conversion  enzyme  levels,  serum
lectrophoresis  and  renal  function.  At  this  point,  we  con-
idered  the  hypothesis  of  Crohn’s  disease  and  given  the
atient’s  complaints  of  intermittent  diarrhea  and  abdominal
iscomfort,  labeled  as  IBS,  an  ileocolonoscopy  was  per-
ormed.  Several  areas  of  erythema  with  aphthous  erosions,
nd  ulcers,  stellar  and  circular,  the  largest  with  10  mm,
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iFigure  1  Esophagogastroduodenoscopy:  lower  third  of  the
esophagus  with  a  typical  ‘‘punched-out’’  ulcer.
were  found  in  the  colon  and  rectum  (Fig.  3);  and  a  pos-
terior  commissure  anal  ﬁssure  was  also  identiﬁed.  Biopsies
showed  architectural  gland  distortion,  goblet  cell  deple-
tion,  cryptitis  and  submucosal  lymphoplasmacytic  inﬁltrate,
ﬁndings  consistent  with  Crohn’s  disease.  The  PPI  was  main-
tained  and  the  patient  was  started  on  swallowed  ﬂuticasone
(500  mcg  two  times  a  day)  with  signiﬁcant  improvement
of  the  proximal  symptoms.  In  turn,  a  decision  was  made
to  start  azathioprine  and  inﬂiximab,  due  to  the  patient’s
young  age,  upper  gastrointestinal  and  colonic  involve-
ment  and  perianal  disease.  An  EGD  repeated  six  months
after  presentation  showed  complete  esophageal  mucosal
healing.Foregut  Crohn’s  disease  has  an  estimated  incidence
of  1--13%  in  patients  with  ileocolonic  disease.  Moreover,
esophageal  Crohn’s  disease  lesions  are  reported  in  15%  of
adults  and  44%  of  pediatric  patients  with  Crohn’s  disease,
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Figure  2  Esophageal  biopsies  histological  examination:  (a)  hemato
the mucosal,  submucosal  and  muscle  layers.  (b)  Hematoxilin  &  eosi
(arrow).igure  3  Ileocolonoscopy:  active  colitis  with  two  superﬁcial
lcers  and  a  deep  stellate  ulcer  in  the  left  colon.
hen  an  EGD  is  systematically  performed,  suggesting  that
his  entity  is  probably  underdiagnosed.1 In  contrast,  isolated
sophageal  Crohn’s  is  extremely  rare  with  very  few  reported
ases.2 The  diagnosis  implies  ruling  out  other  causes  of
sophagitis,  namely,  reﬂux  disease,  medications,  viral,  fun-
al  and  mycobacterial  infections,  sarcoidosis,  vasculitis  and
arcinoma.2 Endoscopic  features  are  not  speciﬁc  and  include
rythema,  erosions  and  ulcers,  aphthous  and  superﬁcial  or
eep  punched-out,  strictures  and  ﬁstulas.2--4 As  for  other
rohn’s  disease  locations,  non-necrotizing  granulomas  are
ncommonly  seen  (7--9%  in  esophageal  biopsies)2 and  a
igh  index  of  suspicion  is  needed  to  consider  this  diagnosis
n  the  absence  of  known  extra-esophageal  Crohn’s  dis-
ase.  Therapeutic  options  include  systemic  corticosteroids,
mmunosupressants  and  anti-TNF,  the  latter  reserved  for
2--5evere  and  refractory  disease. PPIs  have  no  proved  efﬁ-
acy  in  mucosal  healing  and  are  used  for  symptom  relief.
inally,  topical  swallowed  aerosolized  corticosteroids  were
hown  to  induce  esophageal  healing  in  a  recent  case-report
xilin  &  eosin  40×  --  intense  inﬂammatory  inﬁltrate  permeating
n  200×  --  non-caseous  epithelioid  granulomas  with  a  giant  cell
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management. J Crohn’s Colitis. 2010;4:63--101.32  
nd  the  authors  propose  topical  steroids  as  an  effective
djuvant  therapy.6
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